Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
Clinical Research Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
World J Gastroenterol. 2018 Nov 21;24(43):4920-4927. doi: 10.3748/wjg.v24.i43.4920.
To describe the prevalence of posttransplant metabolic syndrome (PTMS) after donation after cardiac death (DCD) liver transplantation (LT) and the pre- and postoperative risk factors.
One hundred and forty-seven subjects who underwent DCD LT from January 2012 to February 2016 were enrolled in this study. The demographics and the clinical characteristics of pre- and post-transplantation were collected for both recipients and donors. PTMS was defined according to the 2004 Adult Treatment Panel-III criteria. All subjects were followed monthly for the initial 6 mo after discharge, and then, every 3 mo for 2 years. The subjects were followed every 6 mo or as required after 2 years post-LT.
The prevalence of PTMS after DCD donor orthotopic LT was 20/147 (13.6%). Recipient's body mass index ( = 0.024), warm ischemia time (WIT) ( = 0.045), and posttransplant hyperuricemia ( = 0.001) were significantly associated with PTMS. The change in serum uric acid levels in PTMS patients was significantly higher than that in non-PTMS patients ( < 0.001). After the 1 mo, the level of serum uric acid of PTMS patients rose continually over a period, while it was unaltered in non-PTMS patients. After transplantation, the level of serum uric acid in PTMS patients was not associated with renal function.
PTMS could occur at early stage after DCD LT with growing morbidity with the passage of time. WIT and post-LT hyperuricemia are associated with the prevalence of PTMS. An increased serum uric acid level is highly associated with PTMS and could act as a serum marker in this disease.
描述心脏死亡后供肝移植(DCD LT)后代谢综合征(PTMS)的流行情况,以及术前和术后的危险因素。
本研究纳入了 2012 年 1 月至 2016 年 2 月期间接受 DCD LT 的 147 名患者。收集了供体和受体的移植前和移植后的人口统计学和临床特征。PTMS 根据 2004 年成人治疗小组-III 标准进行定义。所有患者在出院后最初的 6 个月内每月随访一次,然后每 3 个月随访 2 年。LT 后 2 年,每 6 个月或根据需要随访。
DCD 供体原位 LT 后 PTMS 的患病率为 20/147(13.6%)。受体的体重指数(BMI)( = 0.024)、热缺血时间(WIT)( = 0.045)和移植后高尿酸血症( = 0.001)与 PTMS 显著相关。PTMS 患者的血清尿酸水平变化明显高于非 PTMS 患者( < 0.001)。在 1 个月后,PTMS 患者的血清尿酸水平持续升高,而非 PTMS 患者的血清尿酸水平则保持不变。移植后,PTMS 患者的血清尿酸水平与肾功能无关。
DCD LT 后早期可能发生 PTMS,随着时间的推移,发病率逐渐增加。WIT 和移植后高尿酸血症与 PTMS 的流行有关。血清尿酸水平升高与 PTMS 高度相关,可作为该疾病的血清标志物。